Clinical and Experimental Dermatology最新文献_第10页

Second-intention Healing Combined with ALA-PDT in the Treatment of Periocular Basal Cell Carcinoma. 二次愈合联合 ALA-PDT 治疗眼周基底细胞癌

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-03-10 DOI: 10.1093/ced/llaf114

Xin Huang, Shuaihantian Luo, Yi Zhan, Siqi Fu, Huiming Zhang

{"title":"Second-intention Healing Combined with ALA-PDT in the Treatment of Periocular Basal Cell Carcinoma.","authors":"Xin Huang, Shuaihantian Luo, Yi Zhan, Siqi Fu, Huiming Zhang","doi":"10.1093/ced/llaf114","DOIUrl":"https://doi.org/10.1093/ced/llaf114","url":null,"abstract":"Background: Basal cell carcinoma (BCC) is the most common skin cancer. Recently, aminolaevulinic acid-photodynamic therapy (ALA-PDT) has emerged as a non-invasive treatment for facial lesions.Objectives: This research aimed to evaluate the efficacy and safety of second-intention healing after tumor excision with ALA-PDT in periocular BCC.Methods: A total of 16 patients with periocular BCC from an academic, large metropolitan-based hospital were included in this study. All the patients received marginal resection combined with topical ALA-PDT. No suture was performed, and ALA-PDT treatments (3-6 times) were applied to each patient with 633 nm red light directly after surgical resection. Patient demographics, images, medication, and prognosis were evaluated and recorded. Patient Satisfaction Questionnaire (PSQ) that consists of the overall satisfaction with medical experience (0-10 scores) and cosmetic outcome (0-10 scores) were recorded.Results: 10 women and 6 men aged between 33 to 84 years old periocular BCC (8/16 were nodular type, 2/16 were infiltrative type, 2/16 were nodular cystic type, 1/16 were ulcerative type and 3/16 were unknown type) completed the treatment with good overall satisfaction with medical experience (mean score: 9.5) and cosmetic outcome (mean score: 8.625). No serious complications and scar formation were reported in all the patients. No recurrence of tumor was observed in the long-term follow-up of 1 -3.5 years.Conclusions: Our results indicate that second-intention healing after marginal resection combined with ALA-PDT can reduce the tissue defect and maintain excellent cure rate, offers an alternative and aesthetic treatment for localized periocular BCC.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chromoblastomycosis: a case series from Sumba, eastern Indonesia. 成色菌病：印度尼西亚东部松巴的一个病例系列。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-03-08 DOI: 10.1093/ced/llaf111

Gladys O Siregar, Maria Harianja, Hanggoro T Rinonce, Eddy Zulfikar, Claus Bøgh, Messe R Ataupah, Ruth D Laiskodat, Evivana S Sundari, Hardyanto Soebono, Marlous L Grijsen

引用次数: 0

Pyoderma gangrenosum with extracutaneous involvement: a systematic review. 坏疽性脓皮病伴皮外受累：系统回顾。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-03-08 DOI: 10.1093/ced/llaf104

Sharon I Choe, Moira Shea, Martha Oberg, Elena Paz Munoz, Alex G Ortega-Loayza

引用次数: 0

Co-Production of the 'My SJS Passport' to Support Survivors of Stevens-Johnson Syndrome (SJS) Post Diagnosis and Beyond - A Proof of Concept Study. 共同制作“我的SJS护照”，以支持史蒂文斯-约翰逊综合征（SJS）的幸存者诊断后和以后-概念验证研究。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-03-08 DOI: 10.1093/ced/llaf088

Anita Hanson, Lucy Hampson, Jane Evely, Maria Hill, Nathan Elsdon, Thermutis Nadier Lawson, Jane Burns, Daniel F Carr, Andrew Thompson, Jennifer Downing, Munir Pirmohamed

{"title":"Co-Production of the 'My SJS Passport' to Support Survivors of Stevens-Johnson Syndrome (SJS) Post Diagnosis and Beyond - A Proof of Concept Study.","authors":"Anita Hanson, Lucy Hampson, Jane Evely, Maria Hill, Nathan Elsdon, Thermutis Nadier Lawson, Jane Burns, Daniel F Carr, Andrew Thompson, Jennifer Downing, Munir Pirmohamed","doi":"10.1093/ced/llaf088","DOIUrl":"10.1093/ced/llaf088","url":null,"abstract":"Background: Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening reactions that cause blistering of the skin and mucous membranes. Survivors can experience long term physical and psychological complications. The 'My SJS Passport' was co-produced by the Patient and Public Involvement group and research team at the Wolfson Centre for Personalised Medicine to improve the care and experiences of survivors.Objectives: The aim of the study was to implement the 'My SJS Passport' in a real-world setting for evaluation by those with lived experience of SJS/TEN. The objectives were to assess participant's perceptions of its acceptability and utility when used during appointments with healthcare professionals and to explore participants' perceptions of its value and potential barriers to implementation.Methods: A proof-of-concept study to evaluate the acceptability and usability of the passport using a mixed methods approach.Results: A questionnaire was completed by 19 (86.4%) females and 3 (13.6%) males, while 11/22 participated focus groups. Findings suggest the passport a valuable communication tool, as it acted as the 'patient's voice' and helped in validating diagnosis with healthcare professionals, family and friends.Conclusion: The study provides the first formal evaluation of the passport and showed that the tool is acceptable, functional and of benefit to the user. Minor barriers to implementation were identified, largely due to the COVID-19 pandemic and, to a lesser extent, the passport design. There is no comparable tool in use; thus, based on these preliminary findings, it is thought that the passport has a valuable role in supporting this underserved population.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

General dermatology and dermatology in primary healthcare. 普通皮肤病学和初级保健中的皮肤病学。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-03-08 DOI: 10.1093/ced/llaf112

Conor Larney, Ashling Courtney, Matthew Howard

引用次数: 0

Correction to: Nonablative laser therapy for cutaneous Kaposi sarcoma: a single centre proof-of-concept study of six patients. 纠正：非消融激光治疗皮肤卡波西肉瘤：6例患者的单中心概念验证研究。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-03-07 DOI: 10.1093/ced/llaf077

引用次数: 0

Scabies Severity Score: The Key to Predicting and Preventing Treatment Failures? 疥疮严重程度评分：预测和预防治疗失败的关键？

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-02-28 DOI: 10.1093/ced/llaf107

Iria Neri, Martina Mussi, Silvia Robuffo, Alessandra Gelmetti, Marco Morante, Bianca Maria Piraccini, Marco Adriano Chessa, Corrado Zengarini

引用次数: 0

General dermatology & dermatology in primary health care. 普通皮肤科和初级卫生保健中的皮肤科。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-02-27 DOI: 10.1093/ced/llaf103

Li Jie Helena Yoo, Stephanie L Ryan, Cristina Grechin, Nicola Kearney, Emily Orr, Nicholas Stefanovic, Daniel G Healy, Karen Eustace

引用次数: 0

Paradoxical Development of Reactive Squamous Atypia and Aggressive, Invasive Squamous Cell Carcinoma Following 5-Fluorouracil for Field Cancerization with Concurrent Immunomodulation. 反应性非典型鳞状细胞癌和侵袭性、侵袭性鳞状细胞癌在5-氟尿嘧啶治疗现场癌并发免疫调节后的矛盾发展。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-02-27 DOI: 10.1093/ced/llaf101

Erik Jaklitsch, Lauren D Crow, Amy Petty, Edgar Martinez, Melodi J Whitley, Sarah A Myers, James Feng, Joi B Carter, Anokhi Jambusaria-Pahlajani, Kei S Oh, Jonhan Ho, Melissa Pugliano-Mauro

{"title":"Paradoxical Development of Reactive Squamous Atypia and Aggressive, Invasive Squamous Cell Carcinoma Following 5-Fluorouracil for Field Cancerization with Concurrent Immunomodulation.","authors":"Erik Jaklitsch, Lauren D Crow, Amy Petty, Edgar Martinez, Melodi J Whitley, Sarah A Myers, James Feng, Joi B Carter, Anokhi Jambusaria-Pahlajani, Kei S Oh, Jonhan Ho, Melissa Pugliano-Mauro","doi":"10.1093/ced/llaf101","DOIUrl":"https://doi.org/10.1093/ced/llaf101","url":null,"abstract":"5-fluorouracil (5FU) is a widely prescribed therapy for field cancerization. However, the emergence of cutaneous squamous cell carcinoma (cSCC) after 5FU treatment is poorly described. We report five patients with eruptive cSCCs of varying severity following 5FU treatment for field cancerization from four university hospitals between March 2019 and May 2021. We examined the indications for treatment, immunosuppression status, onset of cSCCs, staging, and outcomes. Patients (3F, 2M; median age 74), were treated with 5FU for field cancerization. Four patients, including two solid-organ transplant recipients, were on immunomodulating therapy. Eruptive cSCCs developed within 3 weeks to 3 months of 5FU treatment, mostly within the treated area. Staging revealed a spectrum of BWH T2b in two patients and BWH T1 in three. Eruptive cSCCs are a poorly characterized adverse event of topical 5FU treatment. High-risk T stage cSCCs, not yet reported and distinct from eruptive squamous atypia, may also develop despite low grade background disease. Inflammation and immunomodulation could contribute to pathogenesis.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Yaws - A Review of Clinical Features, Diagnosis and Treatment. 雅司病的临床特征、诊断和治疗综述。

IF 3.7 4区医学

Clinical and Experimental Dermatology Pub Date : 2025-02-27 DOI: 10.1093/ced/llaf100

Becca L Handley, Serges Tchatchouang, Michael Marks

{"title":"Yaws - A Review of Clinical Features, Diagnosis and Treatment.","authors":"Becca L Handley, Serges Tchatchouang, Michael Marks","doi":"10.1093/ced/llaf100","DOIUrl":"https://doi.org/10.1093/ced/llaf100","url":null,"abstract":"Yaws, a neglected tropical disease caused by Treponema pallidum subsp. pertenue, primarily affects children in impoverished rural areas. It is spread through direct skin contact. The disease progresses through clinical stages. In the primary stage, patients develop a, usually painless, papilloma or ulcer, often on the lower extremities, which is highly contagious. If untreated, this lesion heals spontaneously but may progress to secondary yaws, characterised by disseminated skin lesions, scaly papules and painful hyperkeratotic plaques on the palms and soles. Tertiary cases occur in 10% of untreated individuals and can cause severe disfigurement, but with the wider availability of treatment this is rare today. Though yaws can be treated with benzathine penicillin, oral azithromycin has become the preferred treatment due to its ease of administration. Currently, it is known to be endemic in 16 countries, with the majority of cases found in the Western Pacific, followed by West Africa and parts of South East Asia. The World Health Organization has renewed eradication efforts, targeting global eradication by 2030 through mass drug administration (MDA) campaigns and enhanced diagnostics. However, challenges such as emerging azithromycin resistance, difficulties in achieving high MDA coverage, and potential zoonotic transmission from nonhuman primates threaten progress. Accurate diagnosis is critical, especially in distinguishing yaws from similar skin conditions and ensuring all endemic communities are identified and offered treatment. Strengthening surveillance and enhancing laboratory capacity for molecular diagnostics is essential for the success of the eradication campaign. With sustained effort and innovation, the global eradication of yaws by 2030 remains achievable.","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0